A study to see effects of homoeopathic drug- Trigonella foenum graecum mother tincture in reducing lipid levels in lipid abnormalities of metabolic syndrome.

Evaluation of hypolipidemic effects of homoeopathic mother tincture Trigonella foenum graecum on dyslipidemia of metabolic syndrome- A randomized clinical study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064765

Enrollment

Registered

2024-03-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention1: Trigonella foenum graecum: Trigonella foenum graecum mother tincture 20 drops BD in half cup of water daily for 3 months. Follow up will be in interval of 15 days. Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: 1.In all diagnosed cases of metabolic syndrome according to National cholesterol education programmed guidelines[NCEP ATP 3] and IDF criteria with any one of lipid profile abnormality. 2.Total cholesterol above 200mg/dl 3.LDL-cholesterol above 100mg/dl 4.Triglycerides above 150mg/dl 5.HDL cholesterol below 40mg/dl for men and 50/dl for women 6. Atherosclerosis cardiovascular disease [ASCVD] risk score of 5-19.9% using ACC/AHA CV Risk calculator 7. Patients will be taken irrespective of socioeconomic status. 8. Patients who gave consent form and willing to take part after knowing the study protocol will be included.

Exclusion criteria

Exclusion criteria: 1) Patients with a. LDL cholesterol above 190mg/dl, b. triglycerides above 500mg/dl. c. Patients of diabetes with HbA1C more than 8%. 2) Patients on insulin treatment. 3) Patients with HTN grade 2,3 and serious cardiac illness, chronic kidney disease. 4) Patients who need emergency medical intervention.

Design outcomes

Primary

Measure	Time frame
:To assess the hypolipidemic effects of the intervention on dyslipidemia of metabolic syndrome by evaluating its impact on the lipid profile, including measurements of LDL-C, HDL-C, TG, TOTAL CHOLESTEROLTimepoint: The follow us will be assessed by lipid profile, including measurements of LDL-C, HDL-C, Triglycerides and Total Cholesterol will be done at baseline and after 12 weeks	—

Secondary

Measure	Time frame
:To assess the effects of intervention on overall health of dyslipidemia patients with metabolic syndrome by evaluating its impact on BP, HBA1C, BLOOD SUGAR LEVEL, CHANGES IN BODY WEIGHT, WAIST CIRCUMFERENCE AND BMI.Timepoint: the follow ups taken will be used to assess overall health of dyslipidemia patients with metabolic syndrome in duration of 3 months.	—

Countries

India

Contacts

Public ContactDr Alice Kangjam

Bharati Vidyapeeth (Deemed to be University), Homoeopathic Medical College,Pune

swati.shinde@bharatividyapeeth.edu9890140393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026